Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis

Moxidectin (MOX) is a milbemycin endectocide recently approved by the U.S. FDA for the treatment of onchocerciasis in persons at least 12 years of age. MOX has been shown to have a good safety profile in recent clinical trials. The efficacy of MOX for the treatment of lymphatic filariasis (LF) and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chhonker, Yashpal S., Bjerum, Catherine, Bala, Veenu, Ouattara, Allassane F., Koudou, Benjamin G., Gabo, Toki P., Alshehri, Abdullah, Meïté, Abdoulaye, Fischer, Peter U., Weil, Gary J., King, Christopher L., Budge, Philip J., Murry, Daryl J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482275/
https://www.ncbi.nlm.nih.gov/pubmed/37616301
http://dx.doi.org/10.1371/journal.pntd.0011567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482275/
https://www.ncbi.nlm.nih.gov/pubmed/37616301
http://dx.doi.org/10.1371/journal.pntd.0011567

Ejemplares similares